Valeant Pharmaceuticals International’s acquisition of Bausch & Lomb for $8.7 billion in cash is a big boon for a handful of savvy hedge fund managers, especially Jeffrey Ubben.
Ubben runs the ValueAct Holdings hedge fund out of ValueAct Capital, his San Francisco–based investment firm.